目的 探讨应用辛芳鼻炎胶囊联合氯雷他定片治疗过敏性鼻炎的临床效果。方法 选取2015年6月—2017年6月天津市泰达医院收治的过敏性鼻炎患者122例，随机分成对照组（61例）与治疗组（61例）。对照组患者口服氯雷他定片，10 mg/次，1次/d。治疗组在对照组基础上口服辛芳鼻炎胶囊，6粒/次，3次/d。两组均连续治疗30 d。观察两组患者临床疗效，同时比较治疗前后两组患者鼻部症状评分、理化指标和细胞因子水平变化。结果 治疗后，对照组临床总有效率为80.3%，显著低于治疗组的93.4%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组鼻塞、流涕、喷嚏和鼻痒症状评分及总分均显著降低（P<0.05），且治疗后治疗组鼻部各症状评分明显低于对照组（P<0.05）。治疗后，两组鼻腔总阻力（TNR）值、呼出气一氧化氮（FeNO）水平和血清总免疫球蛋白E（IgE）浓度较治疗前均显著下降（P<0.05），鼻腔最小横截面积（NMCA）值显著增加（P<0.05），且治疗组上述指标治疗后水平明显优于对照组（P<0.05）。治疗后，两组血清白细胞介素（IL）-4、IL-17含量均显著降低（P<0.05），IL-27和转化生长因子（TGF）-β1浓度均显著升高（P<0.05），且治疗组上述细胞因子治疗后水平明显优于对照组（P<0.05）。结论 辛芳鼻炎胶囊联合氯雷他定片治疗过敏性鼻炎可有效控制患者症状，改善鼻腔通气功能，抑制下气道炎症状态，调节免疫平衡。

Objective To investigate the clinical effects of Xinfang Biyan Capsules combined with loratadine in treatment of allergic rhinitis. Methods Patients (122 cases) with allergic rhinitis in Tianjin TEDA Hospital from June 2015 to June 2017 were randomly divided into control (61 cases) and treatment (61 cases) groups. Patients in the control group were po administered with Loratadine Tablets, 10 mg/time, once daily. Patients in the treatment group were po administered with Xinfang Biyan Capsules on the basis of the control group, 6 grains/time, once daily. Patients in two groups were treated for 30 d. After treatment, the clinical efficacy was evaluated, and the change of the nasal symptom scores, the physicochemical indicators and the cytokines levels in two groups before and after treatment was compared. Results After treatment, the clinical efficacy in the control group was 80.3%, which was significantly lower than 93.4% in the treatment group, and there were differences between two groups (P < 0.05). After treatment, the nasal congestion, runny nose, sneeze, rhinocnesmus symptom scores and total scores in two groups were significantly decreased (P < 0.05), and the nasal symptom scores in the treatment group after treatment were significantly lower than those in the control group (P < 0.05). After treatment, the TNR value, FeNO level and serum IgE concentration in two groups were significantly decreased (P < 0.05), the NMCA value was significantly increased (P < 0.05), and these indicators levels in the treatment group after treatment were significantly better than that in the control group (P < 0.05). After treatment, the serum IL-4 and IL-17 levels in two groups were significantly decreased (P < 0.05), the IL-27 and TGF-β1 concentration was significantly increased (P < 0.05), and these cytokines levels in the treatment group after treatment were significantly better than those in the control group (P < 0.05). Conclusion Xinfang Biyan Capsules combined with loratadine in treatment of allergic rhinitis can effectively relieve the symptoms, improve nasal ventilatory function, inhibit the lower airway inflammation and regulate immune balance.